External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores

Cancer Journal from Scientific American

Volumn 3, Issue 2, 1997, Pages 78-87

  Kupelian, Patrick ^a   Katcher, Jerald ^a   Levin, Howard ^a   Zippe, Craig ^a   Suh, John ^a   Macklis, Roger ^a   Klein, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

prognostic factors; prostate specific antigen; prostatectomy; Prostatic neoplasms; radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY;

EID: 0030901909     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Paulson D, Lin G, Hinshaw W et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-504.
2. D'Amico A, Whittington R, Malkowicz S et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-138.
3. Frazier H, Robertson J, Humphrey P et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-518.
4. Partin A, Pound C, Clemens J et al. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
5. Ravery V, Delmas V, Boccon-Gibod L et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-376.
6. Kupelian P, Katcher J, Levin H et al. Correlation of clinical and pathologic factors with rising PSA profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48: 249-260.
7. Kaplan I, Cox R, Bagshaw M. Prostate specific antigen after external beam radiotherapy for prostate cancer: follow-up. J Urol 1993; 149:519-522.
8. Pisansky T, Cha S, Earle J et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-2166.
9. Ritter M, Messing E, Shanahan T et al. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-1217.
10. Zagars G, von Eschenbach A Prognostic factors in prostate cancer: prostate specific antigen - an important marker for prostate cancer treated by external beam radiotherapy. Cancer 1993;72:538-548.
11. Zietman A, Coen J, Shipley W et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate-specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-645.
12. Zagars G, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostatic-specific antigen and disease outcome. Urology 1995;45:476-483.
13. Oesterling J. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
14. Harris E, Albert A: Survivorship Analysis for Clinical Studies. New York: Marcel Dekker Inc., 1991.
15. Ohori M, Wheeler T, Kattan M et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824.
16. Epstein J, Pizov G, Walsh P. Correlation of pathologic findings with progression following radical prostatectomy. Cancer 1993; 71:3582-3593.
17. Catalona W, Bigg S. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990;143:538-544.
18. Stamey T, Villers A, McNeal J et al. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 1990;143:166-173.
19. Ackerman D, Barry J, Wicklund Ret al. Analysis of risk factors associated with prostate cancer extension to the surgical margins and pelvic node metastases at radical prostatectomy. J Urol 1993;150: 1845-1850.
20. Zincke H, Oesterling J, Blute M et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
21. Weldon V, Tavel F, Neuwirth H et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1994;151:1565-1569.
22. Soloway M, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer (The Lupron Depot Neoadjuvant Prostate Cancer Study Group). J Urol 1995;154:424-428.
23. Reiner W, Walsh P. An anatomical approach to the surgical management of dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol 1979;121:198-200.
24. Elder J, Jewett H, Walsh P. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 1982;127:704-706.
25. Sandler H, McLaughlin W, Kish K et al. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32[suppl 1]:141.
26. Hanks G, Lee W, Hanlon A et al. Conformal technique dose escalation in prostate cancer control with higher doses in patients with pretreatment PSA ≥ 10 ng/ml. Int J Radiat Oncol Biol Phys 1995;32[suppl 1]:141-142.
27. Pollack A, Zagars G, Starkshall G et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996;34: 555-564.
28. Stein A, deKernion J, Smith R et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-946.
29. Schellhammer P, El-Mahdi A, Wright G et al. Prostatic-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology 1993;42:13-20.
30. Pilepich M, Krall J, John M et al. Hormonal cytoreducnon in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:813-817.
31. McLeod D, Coffield S, Johnson C et al. Serum PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bN2M0) prostate cancer. J Urol 1996;155:650A
32. Blasko J, Wallner K, Grimm P et al. Prostate specific antigen based disease control following ultrasound guided 125Iodine implantation for stage T1/T2 prostate carcinoma. J Urol 1995;154: 1096-1099.